Video

Developing new measurements for better MS outcomes


 

EXPERT ANALYSIS FROM CMSC 2019

Researchers are working on new tools to objectively measure several domains affected by multiple sclerosis (MS) in hope of improving patient care, according to Jared Srinivasan.

Mr. Srinivasan, a research coordinator at South Shore Neurologic Associates in Patchogue, N.Y., sat down at the annual meeting of the Consortium of Multiple Sclerosis Centers for a video interview summarizing his work on new measurement tools for assessing disease status in MS patients with Mark Gudesblatt, MD, and other colleagues at South Shore Neurologic Associates.

“We are trying to find better ways of measuring disease status, rather than the EDSS [Expanded Disability Status Scale] ... It is not as sensitive as some other measures can be,” Mr. Srinivasan said. “We are trying to shed light on some new tools regarding objectively measuring cognition, manual dexterity, gait, and ocular coherence tomography.”

The overall goal, he said, “is to use a combination of these granular outcome measures to create a bigger picture of a patient’s disease so we can better treat them.”

One of the tools is called Neurotrax, which measures cognition in multiple dimensions (e.g., attention, information processing, motor skills, verbal functioning). With this and other new tools for manual dexterity and its cognitive aspects, as well as other dimensions of MS, the researchers are trying capture a fuller picture of MS in individual patients.

“The end goal of this is that if we can show that MS is such a complex disease that the current tools we are using do not quite capture the full nuances and granularity in it, then we can move toward using better measures that will capture that, which will move patient care forward.”

Mr. Srinivasan had nothing to disclose.

Recommended Reading

MS research: “Our patients can’t wait” for conventional techniques
Journal of Clinical Outcomes Management
MS prevalence estimates reach highest point to date
Journal of Clinical Outcomes Management
Which comorbidities most diminish quality of life in patients with MS?
Journal of Clinical Outcomes Management
Sex differences in MS: It’s the chromosomes, not just the hormones
Journal of Clinical Outcomes Management
New data bolster latitude’s association with MS prevalence
Journal of Clinical Outcomes Management
FDA approves siponimod for relapsing forms of MS
Journal of Clinical Outcomes Management
A blood biomarker for MS: Coming to clinics soon?
Journal of Clinical Outcomes Management
General neurologists lag on prescribing high-efficacy MS drugs
Journal of Clinical Outcomes Management
Hazardous cannabis use in MS linked to anxiety, depression
Journal of Clinical Outcomes Management
MS patients pay big price for breaks from DMT
Journal of Clinical Outcomes Management